AXSM Earnings & Financial Statements
Axsome Therapeutics, Inc.
$166.48
-$6.49(-3.75%)
49
Overall
40
Value
36
Tech
71
Quality
Market Cap
$9.06B
Volume
294.85K
52W Range
$117.30 - $260.19
Target Price
$279.64
AXSM earnings and financial statements: Axsome Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AXSM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $638.50M | $385.69M | $270.60M | $50.04M | - |
| Cost of revenue | $47.48M | $33.30M | $26.07M | $5.20M | - |
| Operating income | -$166.76M | -$280.56M | -$231.82M | -$179.80M | -$124.71M |
| EBITDA | -$173.34M | -$276.53M | -$228.87M | -$181.29M | -$124.63M |
| Net income | -$183.17M | -$287.22M | -$239.24M | -$187.13M | -$130.40M |
| EPS (diluted) | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $689.80M | $568.50M | $588.24M | $331.48M | $87.79M |
| Total liabilities | $601.51M | $511.48M | $397.26M | $221.92M | $72.15M |
| Shareholders’ equity | $88.30M | $57.02M | $190.98M | $109.56M | $15.63M |
| Cash and equivalents | $322.93M | $315.35M | $386.19M | $200.84M | $86.47M |
| Long-term debt | $145.13M | $189.70M | $185.10M | $94.26M | $49.09M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$93.41M | -$128.41M | -$145.08M | -$116.51M | -$108.23M |
| Capital expenditure | -$480.0K | -$270.0K | -$582.0K | -$702.0K | -$308.0K |
| Free cash flow | -$93.89M | -$128.68M | -$145.66M | -$117.21M | -$108.53M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AXSM | $166.48 | -3.8% | 294.85K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Axsome Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW